Intravenous BI 836826 in Combination With Ibrutinib in Relapsed/Refractory CLL Patients Who Have Been Pre-treated With at Least One Prior Line of Systemic Therapy, and Who Are Eligible for Treatment With Ibrutinib

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 23, 2016

Primary Completion Date

June 3, 2019

Study Completion Date

July 9, 2019

Conditions

Leukemia, Lymphocytic, Chronic, B-Cell

Interventions

DRUG

BI 836826

DRUG

Ibrutinib

Standard of Care

Trial Locations (3)

City of Hope, Duarte

Oregon Health and Sciences University, Portland

Dana-Farber Cancer Institute, Boston